Staar Surgical CO

STAAR Surgical Company announced adjustments to its Interim Co-CEO and CFO's compensation, including a base salary increase and a higher annual bonus target.

STAAR Surgical announced preliminary Q1 2026 net sales exceeding $90 million, a significant increase from the prior year, driven by strong performance in China and the Americas.

STAAR Surgical reported an 18.1% net sales increase in Q4 2025 and reduced net loss, signaling a turnaround after a challenging fiscal year marked by significant losses and strategic shifts.

STAAR Surgical Company announced the termination of its Chief Legal Officer and Corporate Secretary, Nathaniel Sisitsky, effective February 4, 2026, who will transition to a consulting role.

STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers following the departure of Stephen C. Farrell, initiating a global search for a permanent CEO.

STAAR Surgical Company announced significant changes to its Board of Directors, including a new Board Chair and the establishment of two new committees, effective January 15, 2026.

STAAR Surgical Company announced a significant increase in net sales and a return to profitability in the first quarter of 2026, largely driven by robust performance in China.

STAAR Surgical Company reported increased net sales and gross profit for Q3 2025, driven by China sales and cost reductions, while facing a significant year-to-date net loss and a proxy contest over its proposed $28.00 per share acquisition by Alcon.

STAAR Surgical Company reported a significant net loss and revenue decline in Q2 2025, primarily driven by reduced sales in China, while announcing a definitive merger agreement with Alcon for $28.00 per share.

STAAR Surgical's Q1 2025 net sales plummeted 45% year-over-year due to a significant drop in China sales and restructuring initiatives.

STAAR Surgical Company's Q3 2024 results show a 10.3% increase in net sales driven by a 9.9% rise in ICL sales, despite some foreign currency headwinds.

STAAR Surgical Company announced a 7% increase in net sales for the second quarter of 2024, driven primarily by growth in ICL sales.

STAAR Surgical reported a substantial net loss and revenue decline in fiscal 2025, primarily driven by macroeconomic challenges and weak consumer demand in China, alongside costs from a terminated merger and leadership changes.

STAAR Surgical's fiscal year 2024 saw a revenue decrease and net loss, primarily due to a significant decline in ICL sales in China, impacting overall financial performance.

STAAR Surgical Company has amended its lease agreement, expanded its facilities, and detailed executive compensation plans in recent filings.

STAAR Surgical Company reports a Director, Lilian Y. Zhou, acquired 3,530 shares of common stock on June 12, 2026.

Deborah J. Andrews, Interim Co-CEO and CFO of STAAR Surgical Co., reported transactions involving performance stock units and common stock.

Warren Foust, Interim Co-CEO and Pres. & COO of STAAR SURGICAL CO, reported transactions involving performance stock units and common stock on May 15, 2026.

Magda Michna, Chief Development Officer at STAAR SURGICAL CO, reported the vesting of performance stock units on May 15, 2026, with a portion withheld for taxes.

STAAR Surgical Co. executive Warren Foust reported a disposition of common stock to cover tax obligations related to vested restricted stock units.

STAAR Surgical Co. reports a transaction where Chief Development Officer Magda Michna sold shares to cover tax obligations.

STAAR Surgical Company has released its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, equity plan amendments, auditor ratification, and executive compensation.

STAAR Surgical Company has adjourned its Special Meeting of Stockholders to January 6, 2026, at Alcon's request, in connection with their merger agreement.

STAAR Surgical Company urges stockholders to vote for the Alcon merger, highlighting the $30.75 per share cash offer and refuting Broadwood Partners' claims.

STAAR Surgical Company reports independent industry analysts and ISS recommend stockholders vote FOR the amended Alcon merger agreement at an increased price of $30.75 per share.

STAAR Surgical Company urges stockholders to vote for its amended merger agreement with Alcon, following a revised recommendation from Institutional Shareholder Services (ISS).

STAAR Surgical refutes activist investor allegations regarding its go-shop process and urges stockholders to accept Alcon's increased all-cash offer of $30.75 per share.

Broadwood Partners and affiliates updated their beneficial ownership in STAAR Surgical Company to 32.6%, with Richard T. LeBuhn ceasing to be a reporting person.

STAAR Surgical Company and activist investor Broadwood Partners reach a cooperation agreement, leading to significant board changes and CEO transition.

STAAR Surgical Company announced the appointment of Christopher Min Fang Wang to its Board of Directors following a cooperation agreement with Broadwood Partners, L.P.

Yunqi Path Capital Master Fund and affiliated entities have increased their beneficial ownership in STAAR SURGICAL CO, now holding up to 6.5% of common stock.

Broadwood Partners has increased its appraisal demands for STAAR Surgical shares, opposing the proposed merger and compensation plans.

Yunqi Capital, a 5.1% shareholder, reiterates its opposition to Alcon's revised $30.75 per share offer for STAAR Surgical, citing an undervalued company and a flawed go-shop process.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.2% of STAAR Surgical Company's common stock as of May 11, 2026.

Madison Avenue Partners and affiliated entities have reported a 5.8% beneficial ownership stake in STAAR Surgical Co.

The Vanguard Group filed an Amendment No. 8 to Schedule 13G for STAAR Surgical Co, reporting 0% beneficial ownership following an internal realignment.

Armistice Capital, LLC and Steven Boyd have reported a complete divestment of their beneficial ownership in STAAR Surgical Co., now holding 0.00% of common stock.

Soleus Capital Master Fund and related entities have reported a 1.0% beneficial ownership stake in STAAR Surgical Company, totaling 500,000 shares.

Armistice Capital, LLC and Steven Boyd have disclosed a 5.67% beneficial ownership stake in STAAR Surgical Co., holding 2,812,000 common shares.